Abigail Zuger
Abstract
The two nonnucleoside reverse transcriptase inhibitor combinations tenofovir/FTC and abacavir/3TC have been jostling for primacy for some years now,
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The two nonnucleoside reverse transcriptase inhibitor combinations tenofovir/FTC and abacavir/3TC have been jostling for primacy for some years now,
Key concepts: Abacavir, Tenofovir, Medicine, Human immunodeficiency virus (HIV), Virology, Antiretroviral therapy, Viral load